Fisher & Paykel leads ASX 200 gains after profit jumps 24%
Make us a preferred source
Make us a preferred source on Google
More news: Shares in Fisher & Paykel surged in afternoon trade and was the top performing stock across the ASX 200 after the company posted a 24% rise in its full-year net profit after tax and hiked its total dividend by 22%.
Shares jumped 7.1% to $29.49 at 1:04pm AEST.
RBC Capital Markets analyst Craig Wong-Pan maintains a “sector perform” view on the stock, with a price target of NZD36 ($29), noting that while the FY26 result and FY27 guidance were in line with consensus expectations, the company historically has a track record of exceeding its initial forecasts.
Fisher & Paykel posts 24% jump in FY profit, hikes dividend
The news: Healthcare equipment maker Fisher & Paykel reported a 24% rise in net profit after tax to NZD468.5 million ($383.5 million) for the 2026 financial year,
The numbers: The result fell just shy of consensus estimates of NZD470.0 million, according to Visible Alpha data.
Total operating revenue was NZD2.3 billion, up 14% year on year, and roughly in line with average forecasts.
The board has approved a final dividend of 33 cents per share, taking the total dividend for the year to 52 cents per share, an increase of 22% over FY25.
Fisher & Paykel has guided for FY27 revenue of between NZD2.45 billion and NZD2.57 billion, and net profit after tax between NZD500 million and NZD550 million.
What they said: “We were especially encouraged by consumables growth, given it occurred during a period in which hospital admissions for seasonal respiratory illnesses in the United States and other major markets appeared to be subdued compared to the previous year,” said managing director and CEO Lewis Gradon.
“This suggests that changing clinical practice continues to be a strong growth driver.”
The sources: ASX, RBC Capital analyst note
